Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Recurrence 2Neoplasm Metastasis 2Delirium 2

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Dexamethasone 15Radiotherapy 14Nivolumab 14Drug Therapy 14Doxorubicin 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Cyclophosphamide 13Radiation 11Pemetrexed 11Cytarabine 11venetoclax 10Vincristine 10Prednisone 10Docetaxel 10Capecitabine 10Trastuzumab 9Temozolomide 8Rituximab 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Haloperidol × 1 year × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡